Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

In this week’s S&P 500 healthcare earnings roundup, 21 of 24 companies beat earnings expectations, while three fell short. On ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

Lilly, meanwhile, is developing a triple receptor agonist, retatrutide, that targets GLP-1, GIP, and glucagon and is also in phase 3. Shares in Eli Lilly rose sharply in pre-market trading today ...